Form 4: ESQ Director Sells Shares Under Pre-Arranged Plan

Esquire Financial Holdings Director Selig Zises sold 17,000 shares of common stock on August 22, 2025, through pre-arranged trading plans.

Summary

• Selig Zises, a Director of Esquire Financial Holdings, Inc. (ESQ), reported the sale of 17,000 shares of common stock.
• The transactions occurred on August 22, 2025, and were executed under a Rule 10b5-1(c) plan, indicating they were pre-arranged.
• Shares sold from a profit sharing plan totaled 8,500, with prices ranging from $99.54 to $100 per share.
• Shares sold from a trust totaled 8,500, with prices ranging from $99.4494 to $99.94 per share.
• Following these transactions, Zises beneficially owns 153,097 shares, including direct holdings (14,963 shares), shares in a profit sharing plan (21,001 shares), shares in a trust (79,033 shares), shares as trustee for a trust (25,500 shares), and shares by an L.P. (12,600 shares).
• The filing also notes various tranches of restricted stock that will vest in equal annual installments starting December 19, 2023, December 16, 2024, December 9, 2025, December 19, 2026, December 3, 2027, and December 15, 2027.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a 10b5-1 plan, which is a common practice for insiders to manage their equity holdings for diversification or liquidity purposes without implying a negative outlook on the company. While it's a reduction in insider ownership, the pre-scheduled nature makes it less indicative of immediate concerns compared to an unscheduled sale.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, which suggests the transactions were pre-scheduled and not based on new, non-public information, potentially mitigating negative market perception.

Negatives

• A Director reducing their stake by selling 17,000 shares, even if pre-planned, can be perceived as a lack of conviction or a move to diversify personal holdings by some investors.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4; the only potential 'risk' is the market's interpretation of insider selling.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's performance or strategic direction, beyond detailing future vesting schedules for restricted stock.

Industry Context

This Form 4 is a routine disclosure of an insider transaction and does not provide information to analyze broader industry trends or competitor actions.

Related Party Transactions

• The sales from the 'profit sharing plan' and 'trust' are indirect beneficial ownerships related to the reporting person, Selig Zises, and are standard disclosures for insider transactions.

Stakeholder Impact

• Shareholders may view the reduction in a director's stake with varying interpretations, from a routine diversification to a potential signal, though the 10b5-1 plan mitigates the latter.

Next Steps

• Continued vesting of restricted stock for the reporting person on various dates through December 2027.

Key Dates

Recommendation

The sale by Director Selig Zises was executed under a pre-arranged 10b5-1 plan, which suggests it was not based on new, material non-public information. While it represents a reduction in insider ownership, it does not inherently signal a change in the company's fundamental outlook or performance. Investors should continue to monitor the company's financial results and broader market conditions rather than making a significant investment decision solely based on this routine insider transaction.

Keywords

Esquire Financial Holdings, ESQ, Insider Trading, Form 4, Stock Sale, Director, Selig Zises, 10b5-1 Plan